ABSTRACT
A pharmacoepidemiological survey was conducted in order to understand the pattern of migraine prophylactic drug utilization by French physicians. Neurologists and primary care physicians completed a phone-mail-phone questionnaire which inquired about migraine prophylactic treatment. French neurologists and PCP made the same use of migraine prophylaxis in terms of indication, time interval between treatment onset and evaluation, and duration. The two most commonly chosen migraine prophylactic agents were dihydroergotamine and beta-blockers. This study also showed the importance of considering quality of life to evaluate efficacy of migraine prophylaxis.
Subject(s)
Adrenergic beta-Antagonists/therapeutic use , Dihydroergotamine/therapeutic use , Migraine Disorders/prevention & control , Neurology , Physicians, Family , Family Practice , France , Humans , Migraine Disorders/epidemiology , Migraine Disorders/physiopathology , Surveys and Questionnaires , TelephoneABSTRACT
Amineptine is a new tricyclic compound with a grafted long aliphatic chain active on Dopamine synaptic release and as such more desinhibitor, safer and short acting. The study was coordinated by a national and 13 local counsellors. It was an open study. Inclusions criteria and results are examined, making obvious that patients responded well according to the Hamilton rating scale for depression (17 item version--16.4 points dropped at day 7th in 43%) and that it is an efficaceous antidepressant.